# Navitoclax in Relapsed or Refractory High-Risk Myelodysplastic Syndrome

> **NCT05564650** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **Thomas Jefferson University** · enrollment: 6 (actual)

## Conditions studied

- Myelodysplastic Syndrome
- Recurrent Myelodysplastic Syndrome
- Refractory Myelodysplastic Syndrome

## Interventions

- **BIOLOGICAL:** Navitoclax
- **DRUG:** Venetoclax
- **DRUG:** Decitabine
- **PROCEDURE:** Bone Marrow Biopsy
- **PROCEDURE:** Biospecimen Collection
- **OTHER:** Laboratory Biomarker Analysis
- **OTHER:** Quality-of-Life Assessment

## Key facts

- **NCT ID:** NCT05564650
- **Lead sponsor:** Thomas Jefferson University
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2023-01-12
- **Primary completion:** 2024-05-03
- **Final completion:** 2026-05-08
- **Target enrollment:** 6 (ACTUAL)
- **Last updated:** 2025-12-08

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05564650

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05564650, "Navitoclax in Relapsed or Refractory High-Risk Myelodysplastic Syndrome". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT05564650. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*